Indian Biotechs Seek To Outsource Drug Marketing To MNCs
This article was originally published in PharmAsia News
Executive Summary
In somewhat of a trend reversal, some Indian biotechs are outsourcing their own drug projects as the drug-making business tightens. Avesthagen and Biocon have their own pipeline of drugs in development, but are discussing possible partnerships with multinational drug makers. Avesthagen has a nutritional molecule in clinical trials and seeks a MNC willing to market the drug while Avesthagen focuses on four other molecules in the pre-clinical stage. Biocon is in a similar situation with an insulin molecule just entering Phase III trials. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.